Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
“No major news at Mural Oncology (MURA), development has been fully halted and the company is pursuing strategic alternatives. My estimation of liquidation value is $3.25/share against a current quote of $2.50/share. There is some good discussion in the comments about the two-year safe harbor for spins (would falloff this November) and Irish takeover rules pushing this towards being acquired or a reverse merger versus a liquidation. BSD Analysis: Mural Oncology plc (MURA) Mural is a distressed post-failure asset shell currently in an active "offer period" under Irish Takeover Rules after abandoning its entire clinical program for nemvaleukin. The investment is a naked bet on a quick cash-out or a reverse merger with another private biotech company, facilitated by its relatively clean balance sheet featuring approximately $144 million in cash as of its last report. The definitive transaction agreement with XOMA Royalty Corporation signals the end-game: a sale of the public shell to realize the residual cash value. Investors are essentially buying a deep discount to cash, expecting the M&A premium to close the gap between the liquidation value and the trading price.” | BULL | Q2 2025 Jun 30, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
